Related Experiment Video
Updated: Dec 31, 2025

Non-thermal Infrared Light Treatment of Ischemia/Reperfusion Injury and Subsequent Analysis of Macrophage Differentiation
Published on: December 30, 2021
Meisoindigo Protects Against Focal Cerebral Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation
Yingze Ye1,2, Tong Jin3, Xu Zhang3
1Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.
Abstract:
Ischemic stroke is a devastating disease with long-term disability. However, the pathogenesis is unclear and treatments are limited. Meisoindigo, a second-generation derivative of indirubin, has general water solubility and is well-tolerated. Previous studies have shown that meisoindigo reduces inflammation by inhibiting leukocyte chemotaxis and migration. In the present study, we investigated the hypothesis that meisoindigo was also protective against ischemic stroke, then evaluated its underlying mechanisms. In vivo, adult male C57BL/6J wild-type mice were used to produce a middle cerebral artery occlusion (MCAO) stroke model. On day three after reperfusion, obvious improvement in neurological scores, infarct volume reduction and cerebral edema amelioration were observed in meisoindigo treatment. Moreover, immunofluorescence staining and western-blot showed that the expression of NLRP3 inflammasome and its associated proteins in neurons and microglia was inhibited by meisoindigo. The effects of Meisoindigo on NLRP3 inflammasome inactivation and increased the M2 phenotype of microglia/macrophage through shifting from a M1 phenotype, which was possibly mediated by inhibition of TLR4/NF-κB. Furthermore, we verified the inhibitory effect of meisoindigo on TLR4/NF-κB signaling pathway, and found that meisoindigo treatment could significantly suppressed the expression of TLR4/NF-κB pathway-associated proteins in a dose-dependent manner, meanwhile, which resulted in downregulation of HMGB1 and IL-1β. Next, we established an in vitro oxygen glucose deprivation/Reperfusion (OGD/R) model in HT-22 and BV2 cells to simulate ischemic conditions. Cytotoxicity assay showed that meisoindigo substantially improved relative cell vitality and in HT-22 and BV2 cells following OGD/R in vitro. After suffering OGD/R, the TLR4/NF-κB pathway was activated, the expression of NLRP3 inflammasome-associated proteins and M1 microglia/macrophage were increased, but meisoindigo could inhibit above changes in both HT-22 and BV2 cells. Additionally, though lipopolysaccharide stimulated the activation of TLR4 signaling in OGD/R models, meisoindigo co-treatment markedly reversed the upregulation of TLR4 and following activation of NLRP3 inflammasome and polarization of M1 microglia/macrophages mediated by TLR4. Overall, we demonstrate for the first time that meisoindigo post-treatment alleviates brain damage induced by ischemic stroke in vivo and in vitro experiments through blocking activation of the NLRP3 inflammasome and regulating the polarization of microglia/macrophages via inhibition of the TLR4/NF-κB signaling pathway.
Insights
Meisoindigo, a novel compound, shows promise in treating ischemic stroke by reducing brain damage and inflammation. It works by inhibiting the NLRP3 inflammasome and regulating microglia polarization via the TLR4/NF-κB pathway.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Ischemic stroke is a leading cause of long-term disability with limited treatment options.
- The precise pathogenesis of ischemic stroke remains unclear, necessitating novel therapeutic strategies.
- Meisoindigo, a water-soluble indirubin derivative, has demonstrated anti-inflammatory properties.
Purpose of the Study:
- To investigate the neuroprotective effects of meisoindigo against ischemic stroke.
- To elucidate the underlying mechanisms of meisoindigo's action in stroke models.
- To evaluate meisoindigo's impact on the NLRP3 inflammasome and microglial polarization.
Main Methods:
- Middle cerebral artery occlusion (MCAO) stroke model in C57BL/6J mice.
- Oxygen-glucose deprivation/reperfusion (OGD/R) models in HT-22 and BV2 cells.
- Immunofluorescence staining, Western blotting, and cytotoxicity assays were employed.
Main Results:
- Meisoindigo treatment significantly improved neurological scores, reduced infarct volume, and alleviated cerebral edema in MCAO mice.
- Meisoindigo inhibited NLRP3 inflammasome activation and promoted M2 microglia/macrophage polarization by suppressing the TLR4/NF-κB pathway.
- In vitro, meisoindigo protected HT-22 and BV2 cells from OGD/R-induced damage and reversed TLR4-mediated inflammatory responses.
Conclusions:
- Meisoindigo exhibits significant neuroprotective effects in both in vivo and in vitro models of ischemic stroke.
- The therapeutic mechanism involves the inhibition of NLRP3 inflammasome activation and modulation of microglial polarization through the TLR4/NF-κB pathway.
- Meisoindigo represents a potential therapeutic agent for ischemic stroke, warranting further clinical investigation.

